RTTNews | Sep 17, 2020 09:50AM EDT

09:50 Thursday, September 17, 2020 (RTTNews.com) - Atossa Therapeutics, Inc. (ATOS) reported a positive interim safety assessment from the second cohort of healthy participants in the phase 1 clinical study using the company's drug candidate AT-301 administered by nasal spray. The positive assessment by the safety committee allows the study to now enroll the next cohort, which will be the third of a total of four cohorts, and the first of two multi-dose, placebo controlled cohorts.

Atossa's CEO said: "Based on rapid enrollment in the first half of the study, we expect to complete enrollment in the remainder of the study very quickly. We are developing our AT-301 nasal spray for home-use because there are no currently FDA-approved treatments to help these patients with early disease to recover faster."

The ongoing phase 1 study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups. The study is being conducted in Australia.

Read the original article on RTTNews ( https://www.rttnews.com/3129521/atossa-reports-second-favorable-safety-review-in-clinical-study-of-at-301-nasal-spray.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved